107 results about "Nonhuman animal" patented technology

The invention discloses a construction method and application of an NMD escape model of an Alport syndrome mouse. A non-human animal model carrying Col4a5 gene c.4432delG frame shift mutation is prepared on the basis of a CRISPR / Cas9 gene editing technology. The method comprises the following steps: co-injecting gRNA of a 49 exon of a targeted Col4a5 gene, homologous recombinant donor oligonucleotide containing c.4432delG mutation and Cas9 nuclease into a mouse fertilized egg, and carrying out embryo transplantation to obtain an F0-generation mutant mouse; a mutation site is verified by combining PCR (Polymerase Chain Reaction) with sequencing, and a stably inherited mutation line is established through two generations of breeding. Through verification, the model accords with pathological characteristics of the Alport syndrome, can stably simulate typical clinical manifestation and pathological characteristics of the human X-linked Alport syndrome, and can be used as an important tool for research of the Alport syndrome.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

The invention relates to a method for constructing a male non-human animal nicotine exposure model, which comprises the following steps: dissolving and extracting contents in a nicotine bag to obtain a nicotine bag content extracting solution; and selecting a male non-human animal, and performing intragastric administration with the nicotine bag content extracting solution to construct the male non-human animal nicotine exposure model. The invention also relates to a nicotine pocket reproductive development safety evaluation method based on the male non-human animal. The method comprises the following steps: taking the male non-human animal nicotine exposure model as a male parent to mate with a normal female non-human animal to generate a filial generation; detecting a parent reproduction index and a filial generation development index; and performing nicotine pocket reproductive development safety evaluation according to the male parent reproductive index and the offspring development index. The nicotine bag reproductive development safety evaluation comprises comparison with a nicotine bag safety standard substance.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The application provides a construction system and device of a non-human animal model of tension pneumothorax, and the system comprises: a fixing unit for fixing the non-human animal; a first processing unit for puncturing a puncture needle to the parietal pleura, making a guide wire pass through the needle cavity of the puncture needle to enter the pleural cavity, and withdrawing the puncture needle; a second processing unit for inserting a catheter along the guide wire to make the catheter enter the pleural cavity, pulling out the guide wire, and fixing the catheter; a third processing unit for unidirectional air injection into the pleural cavity through the catheter; and a fourth processing unit for monitoring the range of pneumothorax, determining that the non-human animal model of tension pneumothorax is obtained when the lung sliding of the injection side chest is greater than or equal to 4 / 6 area and lung points are observed, stopping air injection, and obtaining the non-human animal model of tension pneumothorax. The construction success rate of the application is 100%, the construction process is rapid, repeatable and objective in determination, and the application can provide a rapid and repeatable platform for diagnostic research, decompression technology evaluation and training.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

Provided are genetically modified animals and cells with humanized NKC and / or Ly49 locus. In one aspect, the genetically-modified, non-human animal comprises at an endogenous NKC locus, one or more human NKC genes, and / or at an endogenous Ly49 locus, one or more human KIR genes. In some embodiments, the animal comprises an endogenous Clec1b gene. In one aspect, the animal comprises at a safe harbor locus (e.g., an endogenous Hipp11 orRosa26 gene locus), one or more human KIR genes.

To provide a humanized rodent that expresses a heavy chain containing a VL domain. [Solution] A non-human animal, tissue, cell, and genetic material is provided which includes a modification of an endogenous non-human heavy chain immunoglobulin sequence and contains functional ADAM6 activity in a rodent (e.g., mouse), wherein the non-human animal rearranges the human immunoglobulin light chain gene segment in relation to the heavy chain constant domain and expresses an immunoglobulin-like molecule which contains a human immunoglobulin light chain variable domain fused to the heavy chain constant domain and is a cognitive of a human immunoglobulin light chain variable domain fused to the light chain constant domain.

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.

Embodiments described relate to a medical device including an invasive probe that, when inserted into an animal (e.g., a human or non-human animal, including a human or non-human mammal), may aid in diagnosing and / or treating a lesion of the animal (e.g., a growth or deposit within vasculature that fully or partially blocks the vasculature). The invasive probe may have one or more sensors to sense characteristics of the lesion, including by detecting one or more characteristics of tissues and / or biological materials of the lesion. The medical device may be configured to analyze the characteristics of a lesion and, based on the analysis, provide treatment recommendations to a clinician. Such treatment recommendations may include a manner in which to treat a lesion, such as which treatment to use to treat a lesion and / or a manner in which to use a treatment device.

A genetically modified non-human animal in which an auxin-inducible degron system controls degradation of a target protein in a living body includes: a chromosome containing a first nucleic acid that encodes a mutant TIR1 family protein having a mutation at an auxin-binding site and having affinity to an auxin analog.

The invention provides a variety of novel devices, systems, and methods of utilizing mixed-ionic-electronic conductor (MIEC) materials adapted to function with an applied current or potential. The materials, as part of a circuit, are placed in contact with a part of a human or nonhuman animal body. A sodium selective membrane system utilizing the MIEC is also described.

Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification and characterization of microbiota may include identifying and characterizing the microbiota of potential donors, characterizing the potential donors, and identifying potentially therapeutic microbiota based on analysis of such data from multiple individuals. In some embodiments, the identification and characterization of microbiota may include testing, that is, administering microbiota of potential donors to animals suffering from a disease or condition, documenting any therapeutic response, and optionally identifying and characterizing the microbiota of recipients before and after treatment, and optionally identifying demonstrated therapeutic microbiota. Embodiments of the invention encompass compositions comprising the microbiotia, including solid oral compositions, methods of making these compositions, and methods of treatment of non-human animals suffering from various diseases and conditions with these compositions.

The present disclosure relates to systems, apparatuses, and methods for continuous cultivation and recovery of comestible non-human animal cells in a suspension bioreactor. For example, in one or more implementations, the disclosed methods include cultivating non-human animal cells in suspension culture within a bioreactor vessel, removing a measure of suspension culture from the bioreactor vessel while continuing to provide cell culture media thereto, and recovering a first portion of cultivated non-human animal cells from the removed measure of suspension culture while returning a second portion of cultivated non-human animal cells to the bioreactor vessel. Also, in some implementations, the disclosed systems include at least one sterile output module configured to prevent backflow contamination when recovering cultivated cells and removing spent media during continuous cultivation of non-human animal cells according to the disclosed methods.

Methods for inducing basal cell carcinoma (BCC) or BCC tumors, as well as an inducible non-human animal models of BCC, are defined herein. The methods and animal models comprise targeting Ptch1 and / or a tumor suppressor gene via conditional expression of one or more short hairpin RNAs (shRNAs) in the skin of said animals.

Provided are: a neurodegenerative model animal also exhibiting amyotrophy, the neurodegenerative model animal comprising a nonhuman animal from which both the PNPLA6 and PNPLA7 genes have been deleted; and a method for screening a drug for neurodegenerative disease or a drug for a disease that causes amyotrophy, the screening method involving causing contact of a substance to be examined with said animal or with a biological sample collected from the animal, and using, as an index, an improvement effect with regards to neurodegeneration or amyotrophy of the nonhuman animal or biological sample after contact with the substance to be examined.

Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.

Methods, devices and systems for delivering light therapy to human or non-human animal subjects. Included are shapeable light therapy devices which are formable into different shapes suitable for delivery of therapeutic light to different regions of the subject's body and will retain the desired shape without a need for the use of a strap or other shape-retaining apparatus. Also included are light therapy devices that, in at least some modes of operation, deliver light that is not visible to the human eye and which include indicator(s) to indicate to a user and / or to the subject being treated when non-visible light is actually being emitted.

A nonhuman animal having a chimeric organ including a foreign cell in a body thereof.

A device for indicating entry of a needle into a body cavity, a conduit or a blood vessel of a human or non-human animal has a pressure sensor configured, in use, to be in fluid communication with a pinhole of the needle; and a selectively activated indicator. The device is configured to activate the indicator when a pressure acting on the pressure sensor reaches or is above a minimum pressure threshold, where the minimum pressure threshold is about 25 cmH2O.

Non-human animal cells and non-human animals comprising a humanized Tfrc gene, e.g., at an endogenous Tfrc locus, and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Tfrc gene express a human TfR protein or fragments thereof. Non-human animal cells and non-human animals comprising a humanized Tfrc gene and a knockout mutation in a Gaa gene, e.g., at an endogenous Gaa locus, and methods of using such non-human animal cells and non-human animals are also provided. Such animals are useful to screen anti-human-TfR binding protein based therapies of, e.g., Pompe disease.

To provide non-human animals expressing exogenous terminal deoxynucleotidyltransferase.SOLUTION: Provided herein are methods and compositions relating to non-human animals that express exogenous terminal deoxynucleotidyltransferase (TdT). In certain aspects, provided herein are genetically modified non-human animals that include in their genome an exogenous nucleic acid encoding terminal deoxynucleotidyltransferase (TdT), as well as production and use methods of such non-human animals. In some embodiments, the exogenous TdT is human TdT. In some embodiments, the exogenous TdT is from an endogenous species (eg, in mice, exogenous TdT has a mouse sequence).SELECTED DRAWING: None

A mouse artificial chromosome vector is stable in rodent cells, tissues, and / or individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from mouse chromosome 10 and mouse chromosome 16. A cell or a non-human animal may include the vector. The vector may be used for producing proteins and human antibodies.

The invention is based on the finding that incubating a Cryptosporidium gp40 protein with an aziridine, significantly increases its immunogenicity. When used as a vaccine, this allows a reduction of the dose, which improves economic feasibility and safety. Consequently the aziridine-treated gp40 can now be used as a safe and effective subunit-vaccine for humans or non-human-animals against Cryptosporidiosis. Specifically for new-born ruminants a vaccination by way of colostral transfer was found to be very effective in reducing clinical signs of Cryptosporidiosis, especially diarrhoea.

The present disclosure provides computer-implemented methods for assisting a user in identifying the likelihood that a non-human animal has or will have, does not have or will not have, or is at risk for developing, one or more traits. The methods disclosed herein also include a method for identifying and / or recommending one or more products or services for a non-human animal, where the one or more products or services are specific for one or more traits identified in or projected to appear in a non-human animal.

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.